文献リスト

1）Bogdanos DP, Gershwin ME. What is new in primary biliary cirrhosis? Dig Dis. 2012; 30 Suppl 1: 20-31

2）Heneghan MA, Yeoman AD, Verma S, et al. Autoimmune hepatitis. Lancet. 2013; 382: 1433-44

3）Liberal R, Grant CR, Mieli-Vergani G, et al. Autoimmune hepatitis: a comprehensive review. J Autoimmun. 2013; 41: 126-39

4）Hirschfield GM, Liu X, Han Y, et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet. 2010; 42: 655-7

5）Hirschfield GM, Liu X, Xu C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med. 2009; 360: 2544-55

6）Liu X, Invernizzi P, Lu Y, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet. 2010; 42: 658-60

7）Mells GF, Floyd JA, Morley KI, et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet. 2011; 43: 329-32

8）Nakamura M, Nishida N, Kawashima M, et al. Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet. 2012; 91: 721-8

9）Juran BD, Hirschfield GM, Invernizzi P, et al. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Hum Mol Genet. 2012; 21: 5209-21

10）Liu JZ, Almarri MA, Gaffney DJ, et al. Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis. Nat Genet. 2012; 44: 1137-41

11）Kar SP, Seldin MF, Chen W, et al. Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. Genes Immun. 2013; 14: 179-86

12）Chen RC, Naiyanetr P, Shu SA, et al. Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. Hepatology. 2013; 57: 1498-508

13）Leung PS, Wang J, Naiyanetr P, et al. Environment and primary biliary cirrhosis: electrophilic drugs and the induction of AMA. J Autoimmun. 2013; 41: 79-86

14）Shapira Y, Agmon-Levin N, Renaudineau Y, et al. Serum markers of infections in patients with primary biliary cirrhosis: evidence of infection burden. Exp Mol Pathol. 2012; 93: 386-90

15）Hu C, Deng C, Zhang S, et al. Clinical significance and prevalence of anti-Saccharomyces cerevisiae antibody in Chinese patients with primary biliary cirrhosis. Clin Exp Med. 2013; 13: 245-50

16）Dellavance A, Cancado EL, Abrantes-Lemos CP, et al. Humoral autoimmune response heterogeneity in the spectrum of primary biliary cirrhosis. Hepatol Int. 2013; 7: 775-84

17）Gatselis NK, Zachou K, Norman GL, et al. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. Autoimmunity. 2013; 46: 471-9

18）Katsushima F, Takahashi A, Sakamoto N, et al. Expression of micro-RNAs in peripheral blood mononuclear cells from primary biliary cirrhosis patients. Hepatol Res. 2013. Jul 9. [Epub ahead of print]

19）Ninomiya M, Kondo Y, Funayama R, et al. Distinct microRNAs expression profile in primary biliary cirrhosis and evaluation of miR 505-3p and miR197-3p as novel biomarkers. PLoS One. 2013; 8: e66086

20）Qin B, Huang F, Liang Y, et al. Analysis of altered microRNA expression profiles in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. J Gastroenterol Hepatol. 2013; 28: 543-50

21）Harada K, Kakuda Y, Nakamura M, et al. Clinicopathological significance of serum fractalkine in primary biliary cirrhosis. Dig Dis Sci. 2013; 58: 3037-43

22）Sasaki M, Miyakoshi M, Sato Y, et al. Increased expression of mitochondrial proteins associated with autophagy in biliary epithelial lesions in primary biliary cirrhosis. Liver Int. 2013; 33: 312-20

23）Khan FM, Komarla AR, Mendoza PG, et al. Keratin 19 demonstration of canal of Hering loss in primary biliary cirrhosis: “minimal change PBC”? Hepatology. 2013; 57: 700-7

24）Harada K, Hsu M, Ikeda H, et al. Application and validation of a new histologic staging and grading system for primary biliary cirrhosis. J Clin Gastroenterol. 2013; 47: 174-81

25）Kakuda Y, Harada K, Sawada-Kitamura S, et al. Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems. Hum Pathol. 2013; 44: 1107-17

26）Harada K, Hirohara J, Ueno Y, et al. Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: national data from Japan. Hepatology. 2013; 57: 1942-9

27）Kikuchi T, Hirano K, Genda T, et al. A study of the effects of saliva stimulation by nizatidine on dry mouth symptoms of primary biliary cirrhosis. World J Hepatol. 2013; 5: 90-6

28）Guanabens N, Monegal A, Cerda D, et al. A randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology. 2013 May 17. [Epub ahead of print]

29）Mandai S, Kanda E, Arai Y, et al. Anti-centromere antibody is an independent risk factor for chronic kidney disease in patients with primary biliary cirrhosis. Clin Exp Nephrol. 2013; 17: 405-10

30）Rudic JS, Poropat G, Krstic MN, et al. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012; 12: CD000551

31）Shi TY, Zhang LN, Chen H, et al. Risk factors for hepatic decompensation in patients with primary biliary cirrhosis. World J Gastroenterol. 2013; 19: 1111-8

32）Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology. 2013; 144: 560-69 e7; quiz e13-4

33）Zhang LN, Shi TY, Shi XH, et al. Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: Results of a 14-year cohort study. Hepatology. 2013; 58: 264-72

34）Corpechot C. Primary biliary cirrhosis and bile acids. Clin Res Hepatol Gastroenterol. 2012; 36 Suppl 1: S13-20

35）Honda A, Ikegami T, Nakamuta M, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology. 2013; 57: 1931-41

36）Cash WJ, OʼNeill S, OʼDonnell ME, et al. Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. Liver Int. 2013; 33: 1166-74

37）Hindi M, Levy C, Couto CA, et al. Primary biliary cirrhosis is more severe in overweight patients. J Clin Gastroenterol. 2013; 47: e28-32

38）Genda T, Ichida T, Sakisaka S, et al. Waiting list mortality of patients with primary biliary cirrhosis in the Japanese transplant allocation system. J Gastroenterol. 2013 Mar 12. [Epub ahead of print]

39）Egawa H, Nakanuma Y, Maehara Y, et al. Disease recurrence plays a minor role as a cause for retransplantation after living-donor liver transplantation for primary biliary cirrhosis: A multicenter study in Japan. Hepatol Res. 2013; 43: 502-7

40）Kido M, Watanabe N, Okazaki T, et al. Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling. Gastroenterology. 2008; 135: 1333-43

41）Aoki N, Kido M, Iwamoto S, et al. Dysregulated generation of follicular helper T cells in the spleen trigg ers fatal autoimmune hepatitis in mice. Gastroenterology. 2011; 140: 1322-33 e1-5

42）Maruoka R, Aoki N, Kido M, et al. Splenectomy prolongs the effects of corticosteroids in mouse models of autoimmune hepatitis. Gastroenterology. 2013; 145: 209-20 e9

43）Peiseler M, Sebode M, Franke B, et al. FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol. 2012; 57: 125-32

44）Grant CR, Liberal R, Holder BS, et al. Dysfunctional CD39 regulatory T cells and aberrant control of T helper type 17 cells in autoimmune hepatitis. Hepatology. 2013 Jun 20. [Epub ahead of print]

45）Lapierre P, Beland K, Yang R, et al. Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance. Hepatology. 2013; 57: 217-27

46）Hardtke-Wolenski M, Fischer K, Noyan F, et al. Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4 T cells. Hepatology. 2013; 58: 718-28

47）Ehser J, Holdener M, Christen S, et al. Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis. J Autoimmun. 2013; 42: 39-49

48）Calich AL, Viana VS, Cancado E, et al. Anti-ribosomal P protein: a novel antibody in autoimmune hepatitis. Liver Int. 2013; 33: 909-13

49）Yokokawa J, Kanno Y, Abe K, et al. Anti-nucleosome autoantibodies as markers for autoimmune hepatitis and their correlation with disease activity. Hepatol Res. 2013 Apr 8. [Epub ahead of print]

50）Onji M, Autoimmune Hepatitis Study G. Proposal of autoimmune hepatitis presenting with acute hepatitis, severe hepatitis and acute liver failure. Hepatol Res. 2011; 41: 497

51）Yamamoto K, Miyake Y, Ohira H, et al. Prognosis of autoimmune hepatitis showing acute presentation. Hepatol Res. 2013; 43: 630-8

52）Abe K, Kanno Y, Okai K, et al. Centrilobular necrosis in acute presentation of Japanese patients with type 1 autoimmune hepatitis. World J Hepatol. 2012; 4: 262-7

53）Yoshizawa K, Matsumoto A, Ichijo T, et al. Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatology. 2012; 56: 668-76

54）Ngu JH, Gearry RB, Frampton CM, et al. Predictors of poor outcome in patients with autoimmune hepatitis: A population-based study. Hepatology. 2013; 57: 2399-406

55）van Gerven NM, Verwer BJ, Witte BI, et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol. 2013; 58: 141-7

56）Al-Shamma S, Eross B, McLaughlin S. Use of a xanthine oxidase inhibitor in autoimmune hepatitis. Hepatology. 2013; 57: 1281-2

57）de Boer YS, van Gerven NM, de Boer NK, et al. Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis. Aliment Pharmacol Ther. 2013; 37: 640-6

58）Burak KW, Swain MG, Santodomino-Garzon T, et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol. 2013; 27: 273-80

59）Weiler-Normann C, Schramm C, Quaas A, et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol. 2013; 58: 529-34

60）Zhao XY, Rakhda MI, Wang TI, et al. Immunoglobulin g4-associated de novo autoimmune hepatitis after liver transplantation for chronic hepatitis B- and C-related cirrhosis and hepatocellular carcinoma: a case report with literature review. Transplant Proc. 2013; 45: 824-7

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp